Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label studyMyrthe J. van Dijk, Eduard J. van Beers, Minke A.E. Rab et al.|American Journal of Hematology|2022Cited by 45
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label studyMyrthe J. van Dijk, Eduard J. van Beers, Minke A.E. Rab et al.|Blood Advances|2023Cited by 32
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzymeMyrthe J. van Dijk, Richard van Wijk, Andreas Glenthøj et al.|Blood Reviews|2023Cited by 20
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell diseaseMyrthe J. van Dijk, Richard van Wijk, Titine Ruiter et al.|HemaSphere|2024Cited by 14
A novel missense variant in <scp><i>ATP11C</i></scp> is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemiaMyrthe J. van Dijk, Richard van Wijk, Brigitte A. van Oirschot et al.|American Journal of Hematology|2023Cited by 12